Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 8 Fallopian Tube Neoplasms 6 Breast Neoplasms 5 Sarcoma 3 Ovarian Cancer Recurrent 3 Carcinoma, Ovarian Epithelial 3 Sarcoma, Ewing 2 Neoplasm Metastasis 2 Leiomyosarcoma 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Vaccinia 1 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Sarcoma, Synovial 1 Rhabdomyosarcoma 1 Recurrence 1 Peritoneal Neoplasms 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Osteosarcoma 1 Low Grade Serous Ovarian Cancer 1 Liposarcoma 1 Hodgkin Disease 1 Histiocytoma, Malignant Fibrous 1 HER2-negative Breast Cancer 1 Gliosarcoma 1 Glioblastoma 1 Endometrial Neoplasms 1 Dermatofibrosarcoma 1

Interventions

trastuzumab deruxtecan 1 taxane 1 sacituzumab govitecan 1 liposomal doxorubicin 1 eribulin 1 Vinorelbine 1 Paclitaxel 1 Gemcitabine 1 Epirubicin 1 Docetaxel 1 Cyclophosphamide 1 Carboplatin 1 Capecitabine 1 Anthracyclines 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × HER2-negative Breast Cancer × liposomal doxorubicin × Clear all

NCT06102824 2024-11-25

ORIENTA

Guangdong Provincial People's Hospital

Phase 2 Recruiting

HER2-negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡